AdaptHealth Corp.

AdaptHealth Corp.(AHCO)の株式分析

$6.030

+0.186 (+3.08%)終値時点

Loading chart…
高値
6.075
始値
5.820
出来高加重平均価格
5.98
出来高
1.56M
時価総額
1.31B
安値
5.820
売買代金
9.31M
EV/EBITDA(TTM)
6.11

AdaptHealth Corp. and subsidiaries are engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under three segments that align with its product categories: Sleep Health, Respiratory Health, and Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Wellness at Home segment provides home medical equipment and services to patients in their homes, including those who have been discharged from acute care and other facilities.

AI分析 of AdaptHealth Corp. (AHCO)

中立

Currently, AdaptHealth Corp (AHCO) is not a strong buy due to its recent financial struggles, including a significant Q2 loss of $1.07 per share compared to an expected profit of $0.15. The stock has also seen a year-to-date decline of 37.75%, indicating ongoing market challenges. However, insider buying has surged by 20850.77% over the last month, suggesting some confidence from company insiders. The current price of $6.02 is below the analyst price targets, which range from $9 to $10, indicating potential upside but also significant risks.

バリュエーション指標

AdaptHealth Corp.(AHCO)の現在の予想PERは7.78で、5年平均は12.39です。

予想PER

割安
5年平均 P/E
12.39
現在のP/E
7.78
割高
16.80
割安
7.99

予想EV/EBITDA

適正
5年平均 EV/EBITDA
5.93
現在のEV/EBITDA
6.11
割高
7.06
割安
4.79

予想PSR

割安
5年平均 P/S
0.52
現在のP/S
0.26
割高
0.75
割安
0.29

Alphio AI による AHCO の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%AHCO

$9.12

シナリオ価格

基

基本

基本 · 50%AHCO

$8.64

シナリオ価格

弱

弱気

弱気 · 25%AHCO

$7.24

シナリオ価格

AHCO を保有するクジラ

D

Deerfield Management Company, L.P.

+ を保有AHCO

-1.74%

3か月リターン

R

Reinhart Partners, LLC

+ を保有AHCO

-2.12%

3か月リターン

K

Kennedy Capital Management LLC

+ を保有AHCO

-2.90%

3か月リターン

イベントタイムライン

2026-09-08 (ET)

16:30:00

AdaptHealth Appoints Harriss T. Currie as CFO

2026-08-04 (ET)

12:00:00

Major Averages Surge Again, Tech Shares Lead Gains

07:30:00

AdaptHealth Reports Q2 Revenue of $740.3M, Lowers Full-Year Outlook

07:30:00

Company Revises FY2026 Financial Guidance to $2.85B-$2.89B

2026-07-20 (ET)

17:00:00

AdaptHealth Divests Diabetes Health Business to Cardinal Health for $235M

ニュース

AHCO のよくある質問 — Alphio AI が回答

AdaptHealth Corp. and subsidiaries are engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under three segments that align with its product categories: Sleep Health, Respiratory Health, and Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Wellness at Home segment provides home medical equipment and services to patients in their homes, including those who have been discharged from acute care and other facilities. It operates in the Healthcare sector (SERVICES-HOME HEALTH CARE SERVICES industry).

Currently, AdaptHealth Corp (AHCO) is not a strong buy due to its recent financial struggles, including a significant Q2 loss of $1.07 per share compared to an expected profit of $0.15. The stock has also seen a year-to-date decline of 37.75%, indicating ongoing market challenges. However, insider buying has surged by 20850.77% over the last month, suggesting some confidence from company insiders. The current price of $6.02 is below the analyst price targets, which range from $9 to $10, indicating potential upside but also significant risks.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める